Prime Medicine, Inc. (PRME)
| Market Cap | 852.22M |
| Revenue (ttm) | 591,000 |
| Net Income (ttm) | -204.50M |
| Shares Out | 120.03M |
| EPS (ttm) | -2.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 528,298 |
| Open | 7.05 |
| Previous Close | 7.04 |
| Day's Range | 6.87 - 7.18 |
| 52-Week Range | 4.11 - 17.20 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 16.33 (+130.65%) |
| Earnings Date | May 10, 2024 |
About PRME
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunothe... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for PRME stock is "Strong Buy." The 12-month stock price forecast is $16.33, which is an increase of 130.65% from the latest price.
News
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie...
Alphabet Bought Up Two Slumping Stocks
YouTube and Google parent Alphabet bought more GitLab and Prime Medicine stock in the first quarter.
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
-- Announced FDA clearance of first-ever IND application for a Prime Editing product, PM359, for the treatment of CGD; initial data from planned Phase 1/2 clinical trial expected in 2025 -- -- Present...
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Gran
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter cl...
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
-- Maturing into clinical-stage company; on-track to file IND application or CTA for PM359 in 1H 2024, with initial data expected in 2025 -- -- Progressing broader portfolio across core areas of focus...
Prime Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Announces Pricing of Upsized Public Offering
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Cystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CF
BETHESDA, Md.--(BUSINESS WIRE)--Today, the Cystic Fibrosis Foundation announced that it will provide up to $15 million to Prime Medicine for preclinical research into gene editing for cystic fibrosis....
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine to Present at Upcoming Investor Conferences
Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therap...
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- S...
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well Above Anticipated T...
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
New In Vivo Data in Humanized Mouse Model Demonstrate that Prime Editing Can Correct Predominant Mutations Accounting for Approximately 60% of Patients with RHO adRP Up to 70% Precise Correction at RH...
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi...
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annua...
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
-- Collaboration combines Prime Medicine's Prime Editing platform with Cimeio Therapeutics' Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimen...
Prime Medicine to Present at Investor Conferences in June
CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie...
Prime Medicine to Present at Virtual Investor Conferences in May
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie...
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
Data demonstrated Prime Editors efficiently, reproducibly and durably corrected the causative mutation of CGD, supporting advancement of development candidate PM359